GLP1R and cerebrovascular disorder: There were differences between group A and group B in clinical characteristics (e.g., 2,275 patients in group A vs 2,610 patients in group B: initiation of SGLT-2i or GLP-1 RAs, 1.6% vs 3.1%; coronary artery disease, 71.2% vs 74.6%; cerebrovascular disease, 20.1% vs 23.3%; heart failure, 30.6% vs 35.8%; hypertension, 88.8% vs 81.3%; hyperlipidemia, 86.7% vs 75.8%; CKD stage 3, 18.7% vs 21.5%; mean [SD] Charlson Comorbidity Index score, 4.0 [2.7] vs 4.4 [2.9]) (Table 1).